ArticleFrontiers in bioengineering and biotechnology2020
Selective Cytotoxic Activity of Prodigiosin@halloysite Nanoformulation.
Article in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 55 citations in OpenAlex.
- Engineering of Extracellular Vesicles for Targeted Delivery of Prodigiosin.Biotech (Basel (Switzerland)) · 2026Article
- Comparative inhibitory effects of zeolite, sepiolite, and kaolinite on A549 lung cancer cells.PloS one · 2026Article
- Antiproliferative Activity of Prodigiosin Derived From Serratia marcescens VITSD2: An In Vitro and In Silico Approach.MicrobiologyOpen · 2025Article
- Promising Prodiginins Biological Activities.Chemistry & biodiversity · 2025Review
- Relationships of Prodiginins Mechanisms and Molecular Structures to their Antiproliferative Effects.Anti-cancer agents in medicinal chemistry · 2024Review
- A comprehensive profiling of quorum quenching by bacterial pigments identifies quorum sensing inhibition and antibiofilm action of prodigiosin against Acinetobacter baumannii.Archives of microbiology · 2023Article
- Bioactive Compound-Loaded Nanocarriers for Hair Growth Promotion: Current Status and Future Perspectives.Plants (Basel, Switzerland) · 2023Review
- Intratumour microbiota modulates adrenocortical cancer responsiveness to mitotane.Endocrine-related cancer · 2023Article
- Carbon dots labeledFrontiers in bioengineering and biotechnology · 2023Article
- Recent Advances in Prodigiosin as a Bioactive Compound in Nanocomposite Applications.Molecules (Basel, Switzerland) · 2022Review
- Prodigiosin: a promising biomolecule with many potential biomedical applications.Bioengineered · 2022Review
- Hydrosoluble Perylene Monoimide-Based Telomerase Inhibitors with Diminished Cytotoxicity.ACS omega · 2022Article
- Nanomechanical Atomic Force Microscopy to Probe Cellular Microplastics Uptake and Distribution.International journal of molecular sciences · 2022Article
- Forskolin-Loaded Halloysite Nanotubes as Osteoconductive Additive for the Biopolymer Tissue Engineering Scaffolds.Polymers · 2021Article
- Toxicological Evaluations in Macrophages and Mice Acutely and Chronically Exposed to Halloysite Clay Nanotubes Functionalized with Polystyrene.ACS omega · 2021Article
- Conversion of Organic Dyes into Pigments: Extraction of Flavonoids from Blackberries (Molecules (Basel, Switzerland) · 2021Article
- Clay Nanotube Immobilization on Animal Hair for Sustained Anti-Lice Protection.Pharmaceutics · 2021Article
- Butylcycloheptylprodigiosin and undecylprodigiosin are potential photosensitizer candidates for photodynamic cancer therapy.Molecular biology reports · 2021Article
- Comparative Toxicity of Fly Ash: An In Vitro Study.Molecules (Basel, Switzerland) · 2021Article
- Facile Fabrication of Natural Polyelectrolyte-Nanoclay Composites: Halloysite Nanotubes, Nucleotides and DNA Study.Molecules (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prodigiosin, a bioactive secondary metabolite produced by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.